Theriva Biologics, Inc. (TOVX) Income Statement
TOVX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsTOVX revenue and net income
TOVX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
TOVX quarterly EPS vs estimates
Theriva Biologics beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 11, 2026.
TOVX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $108,000 | $137,000 | $135,000 | $268,000 | $87,000 | $201,000 | $240,000 | $272,000 | $245,000 | $157,000 |
| Gross profit | −$108,000 | −$137,000 | −$135,000 | −$268,000 | −$87,000 | −$201,000 | −$240,000 | −$272,000 | −$245,000 | −$157,000 |
| Research & development | $8.6M | $12.0M | $14.3M | $11.7M | $7.8M | $5.1M | $11.1M | $11.8M | $18.8M | $29.1M |
| Sales, general & admin | $15.4M | $7.4M | $7.2M | $7.6M | $6.5M | $5.0M | $4.6M | $5.7M | $7.5M | $10.1M |
| Total operating expenses | $14.9M | $26.3M | $21.4M | $21.6M | $14.3M | $10.2M | $15.7M | $17.6M | $26.3M | $39.3M |
| Operating income | −$15.0M | −$26.3M | −$21.4M | −$21.6M | −$14.3M | −$10.2M | −$15.7M | −$17.6M | −$26.3M | −$39.3M |
| Interest income | $287,000 | $697,000 | $1.4M | $512,000 | $6,000 | $44,000 | $283,000 | $67,000 | — | — |
| Interest expense | — | — | — | $430,000 | $93,000 | — | — | — | — | — |
| Income before taxes | −$23.7M | −$25.7M | −$20.0M | −$21.1M | −$14.3M | −$10.1M | −$15.4M | −$13.4M | −$15.5M | −$27.8M |
| Income taxes | $1.5M | — | −$1.6M | −$1.4M | −$94,000 | −$117,000 | −$360,000 | −$4.2M | −$11.1M | −$12.0M |
| Net income | −$25.2M | −$25.7M | −$18.3M | −$19.7M | −$14.2M | −$10.0M | −$15.3M | −$13.4M | −$15.2M | −$27.3M |
| EBITDA | −$23.6M | −$19.3M | −$22.0M | −$19.2M | −$14.2M | −$10.0M | −$15.4M | −$17.3M | −$26.0M | −$39.1M |
| EPS (diluted) | −$4.03 | −$36.55 | −$21.09 | −$16.63 | −$52.50 | −$83.10 | −$129.40 | −$1002.50 | −$1655.50 | −$2750.38 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $300,000 | $0 | $0 | $0 | $0 | $154,000 | $0 | $0 | $0 | $758,000 | $0 |
| Cost of revenue | — | $24,000 | $27,000 | — | $27,000 | $26,000 | −$185,000 | $33,000 | $38,000 | $39,000 | −$339,000 | $134,000 |
| Gross profit | — | $276,000 | −$27,000 | — | −$27,000 | −$26,000 | $185,000 | −$33,000 | −$38,000 | −$39,000 | $339,000 | −$134,000 |
| Research & development | $1.3M | $355,000 | $1.1M | $2.6M | $2.0M | $3.0M | $2.9M | $2.7M | $3.0M | $3.5M | $4.2M | $4.0M |
| Sales, general & admin | $2.0M | $2.1M | $931,000 | $1.9M | $11.2M | $1.4M | $1.7M | $2.3M | $1.6M | $2.0M | $2.0M | $1.7M |
| Total operating expenses | $3.3M | $2.4M | $2.1M | $4.4M | $13.1M | $4.4M | $4.6M | $7.9M | $8.5M | $5.4M | $6.2M | $4.2M |
| Operating income | −$3.3M | −$2.1M | −$2.1M | −$4.4M | −$13.1M | −$4.4M | −$4.4M | −$7.9M | −$8.5M | −$5.4M | −$5.9M | −$4.2M |
| Interest income | $79,000 | $82,000 | $72,000 | $65,000 | $54,000 | $96,000 | $138,000 | $158,000 | $173,000 | $228,000 | $312,000 | $382,000 |
| Interest expense | — | — | — | — | — | — | $697,000 | — | — | — | $408,000 | — |
| Income before taxes | −$3.2M | −$2.0M | −$2.0M | −$4.4M | −$13.1M | −$4.3M | −$4.4M | −$7.7M | −$8.3M | −$5.2M | −$5.9M | −$3.8M |
| Income taxes | — | — | $1.5M | — | — | — | $1,000 | — | — | −$4,276 | −$424,000 | −$527,000 |
| Net income | −$3.2M | −$2.0M | −$2.0M | −$4.4M | −$13.1M | −$4.3M | −$4.4M | −$7.7M | −$8.3M | −$5.2M | −$5.5M | −$3.3M |
| EBITDA | −$3.2M | −$2.0M | −$2.0M | −$4.3M | −$13.0M | −$4.4M | −$4.4M | −$5.0M | −$4.4M | −$5.1M | −$5.8M | −$5.8M |
| EPS (diluted) | −$0.07 | −$0.05 | −$0.10 | −$0.45 | −$1.93 | −$1.55 | −$11.49 | −$6.81 | −$10.75 | −$7.50 | −$0.34 | −$4.75 |
| Gross margin | — | 92.0% | — | — | — | — | 120.1% | — | — | — | 44.7% | — |
| Operating margin | — | −700.0% | — | — | — | — | −2,853.9% | — | — | — | −775.5% | — |
| Net margin | — | −681.3% | — | — | — | — | −2,887.7% | — | — | — | −723.6% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in TOVX's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
TOVX financial results
Theriva Biologics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $25.2 million. Diluted earnings per share came to −$4.03.
See the TOVX stock overview for the latest quote and news, or the TOVX chart for price history and technical indicators.
TOVX income statement FAQ
Does Theriva Biologics have revenue?
Theriva Biologics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Theriva Biologics profitable?
No. Theriva Biologics reported a net loss of $25.2 million in fiscal 2025.
How much does Theriva Biologics spend on research and development?
Theriva Biologics spent $8.6 million on research and development in fiscal 2025.
What are Theriva Biologics's earnings per share?
Theriva Biologics earned $-4.03 per diluted share in fiscal 2025, compared with $-36.55 a year earlier.
When will Theriva Biologics report its next earnings?
Theriva Biologics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Theriva Biologics's fiscal year end?
Theriva Biologics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.